MSX-122
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 201961

CAS#: 897657-95-3

Description: MSX-122 is a n orally bioavailable inhibitor of CXCR4 with potential antineoplastic and antiviral activities. CXCR4 inhibitor MSX-122 binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1) to the CXCR4 receptor and receptor activation, which may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the GPCR (G protein-coupled receptor) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; it is also a co-receptor for HIV entry into T cells. The chemical structure of MSX-122 is very similar to that of WZ811.


Chemical Structure

img
MSX-122
CAS# 897657-95-3

Theoretical Analysis

MedKoo Cat#: 201961
Name: MSX-122
CAS#: 897657-95-3
Chemical Formula: C16H16N6
Exact Mass: 292.14364
Molecular Weight: 292.34
Elemental Analysis: C, 65.74; H, 5.52; N, 28.75

Price and Availability

Size Price Availability Quantity
5.0mg USD 90.0 Same Day
10.0mg USD 150.0 Same Day
25.0mg USD 250.0 Same Day
50.0mg USD 450.0 Same Day
100.0mg USD 650.0 Same Day
200.0mg USD 950.0 Same Day
500.0mg USD 1650.0 2 Weeks
Bulk inquiry

Synonym: MSX122; MSX 122; MSX-122.

IUPAC/Chemical Name: N,N'-(1,4-phenylenebis(methylene))bis(pyrimidin-2-amine)

InChi Key: PXZXYRKDDXKDTK-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H16N6/c1-7-17-15(18-8-1)21-11-13-3-5-14(6-4-13)12-22-16-19-9-2-10-20-16/h1-10H,11-12H2,(H,17,18,21)(H,19,20,22)

SMILES Code: C1(CNC2=NC=CC=N2)=CC=C(CNC3=NC=CC=N3)C=C1

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: MSX-122 is an active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions, with an IC50 of ∼10 nM.
In vitro activity: To determine whether MSX-122 directly binds to the CXCL12 site on CXCR4, a highly sensitive radiotracer technique, using a fluorine-18 radiolabeled MSX-122 analog (MSX-122F) in which one pyrimidine ring of MSX-122 was labeled by fluorine-18 (Figure 1D) was utilized. It was postulated that MSX-122 bound to CXCR4 can interfere with the “lock and key” mechanism between CXCR4 and CXCL12, which can result in inhibiting key functional signaling such as Matrigel invasion and cAMP modulation without displacing CXCL12. 100 nM MSX-122 effectively blocked invasion of 78% MDA-MB-231 cells while the same concentration of AMD3100 blocked invasion of 62% cells. CXCR4 and CXCL12 are also known to play critical roles in endothelial cell migration and tubular organization. While AMD3100 at 100 nM blocked 43% of CXCL12-induced tubular network formation, MSX-122 blocked 63% at the same concentration (Figure 2B). In conclusion, MSX-122, a small novel molecule that is a partial CXCR4 antagonist without mobilizing stem cells has been developed. This can be safer for long-term blockade of metastasis than other reported CXCR4 antagonists. Reference: PLoS One. 2012; 7(4): e34038. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317778/
In vivo activity: To test the impact of CXCR4 blockade with either AMD3100 or MSX-122 on development of radiation-induced PF, AMD3100, 10 mg/kg, s.c. or MSX-122, 10 mg/kg i.p. was administered to Female C57BL/6 mice for 20-weeks. It was found from the initial pilot experiment that a single 20-Gy dose to the lung at the 20-week time-point resulted in fully 90% of untreated mice developing PF confirmed by both trichrome staining-positivity (maximum score 12) and CT scan showing a significant volume with density > -200 HU. Both histology-based and CT-based assessments show that MSX-122 significantly attenuated the development of fibrosis by 70%, while AMD3100 only trended towards reduction in fibrosis (Figure 5A). Representative micrographs of trichrome-staining in each group at low and high power are shown, with obvious blue staining in the vehicle only group indicating significant deposition of collagen (Figure 5B). The AMD3100-treated group showed 50% mortality during the 20-weeks of treatment, while no mortality was observed in the MSX-122- or vehicle-treated (irradiated) groups. These results suggest that the CXCR4/CXCL12-axis is critical in the development of radiation-induced PF in a mouse model and that CXCR4 inhibition may alleviate potential radiation-induced lung injury. Examining possible use of MSX-122 for blocking PF among patients undergoing thoracic irradiation warrants further investigations. Reference: PLoS One. 2013; 8(11): e79768. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820649

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Soluble in DMSO 0.2 0.7

Preparing Stock Solutions

The following data is based on the product molecular weight 292.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, Klapproth JM, Yang H, Grossniklaus HE, Xu J, Rojas M, Voll RJ, Goodman MM, Arrendale RF, Liu J, Yun CC, Snyder JP, Liotta DC, Shim H. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012;7(4):e34038. doi: 10.1371/journal.pone.0034038. Epub 2012 Apr 2. PMID: 22485156; PMCID: PMC3317778. 2. Shu HK, Yoon Y, Hong S, Xu K, Gao H, Hao C, Torres-Gonzalez E, Nayra C, Rojas M, Shim H. Inhibition of the CXCL12/CXCR4-axis as preventive therapy for radiation-induced pulmonary fibrosis. PLoS One. 2013 Nov 7;8(11):e79768. doi: 10.1371/journal.pone.0079768. PMID: 24244561; PMCID: PMC3820649.
In vitro protocol: 1. Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, Klapproth JM, Yang H, Grossniklaus HE, Xu J, Rojas M, Voll RJ, Goodman MM, Arrendale RF, Liu J, Yun CC, Snyder JP, Liotta DC, Shim H. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012;7(4):e34038. doi: 10.1371/journal.pone.0034038. Epub 2012 Apr 2. PMID: 22485156; PMCID: PMC3317778.
In vivo protocol: 1. Shu HK, Yoon Y, Hong S, Xu K, Gao H, Hao C, Torres-Gonzalez E, Nayra C, Rojas M, Shim H. Inhibition of the CXCL12/CXCR4-axis as preventive therapy for radiation-induced pulmonary fibrosis. PLoS One. 2013 Nov 7;8(11):e79768. doi: 10.1371/journal.pone.0079768. PMID: 24244561; PMCID: PMC3820649. 2. Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, Klapproth JM, Yang H, Grossniklaus HE, Xu J, Rojas M, Voll RJ, Goodman MM, Arrendale RF, Liu J, Yun CC, Snyder JP, Liotta DC, Shim H. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012;7(4):e34038. doi: 10.1371/journal.pone.0034038. Epub 2012 Apr 2. PMID: 22485156; PMCID: PMC3317778.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Shu HK, Yoon Y, Hong S, Xu K, Gao H, Hao C, Torres-Gonzalez E, Nayra C, Rojas M, Shim H. Inhibition of the CXCL12/CXCR4-Axis as Preventive Therapy for Radiation-Induced Pulmonary Fibrosis. PLoS One. 2013 Nov 7;8(11):e79768. doi: 10.1371/journal.pone.0079768. PubMed PMID: 24244561; PubMed Central PMCID: PMC3820649.

2: Ziarek JJ, Liu Y, Smith E, Zhang G, Peterson FC, Chen J, Yu Y, Chen Y, Volkman BF, Li R. Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction. Curr Top Med Chem. 2012;12(24):2727-40. PubMed PMID: 23368099; PubMed Central PMCID: PMC3839847.

3: Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, Klapproth JM, Yang H, Grossniklaus HE, Xu J, Rojas M, Voll RJ, Goodman MM, Arrendale RF, Liu J, Yun CC, Snyder JP, Liotta DC, Shim H. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012;7(4):e34038. doi: 10.1371/journal.pone.0034038. Epub 2012 Apr 2. PubMed PMID: 22485156; PubMed Central PMCID: PMC3317778.

4: de Nigris F, Schiano C, Infante T, Napoli C. CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64. Review. PubMed PMID: 22376154.



Additional Information

MSX-122 is a potent inhibitor of the chemokine receptor CXCR4, which is activated by stromal derived factor-1 (SDF-1). The interaction between SDF-1 and CXCR4 has been shown to promote chemotaxis and angiogenesis in multiple cancer cell types. In preclinical studies, MSX-122 has displayed a favorable pharmacodynamic and safety profile while inhibiting the function of CXCR4, thus affecting downstream cellular events. [source: http://www.gabio.org/pr_details.aspx?subid=121] .